Value through Innovation27 November 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication


Respimat® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim


ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung


Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union


Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropathy in Pima Indians


Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions


FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD


Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment


Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib* for the treatment of IPF.


New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy1,2,3


New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups


Data Comparison shows onset of action of oral hyoscine butylbromide already as early as 15 minutes


Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate


Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung


First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation


2014: Boehringer Ingelheim positioned for future growth with product launches


New international survey of lung cancer oncologists highlights underutilization of personalized treatments

- For media outside the US, the UK and Canada only

Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders